In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Ischemia Technologies Produce the Next Big Cardiac Marker?

Executive Summary

In recent years, some creative diagnostic companies have applied pharmaceutical-like marketing techniques to launches of their flagship products. Five-year-old Ischemia Technologies' launch strategy for its cardiac marker, ischemia-modified albumin (IMA) is based on tenets gleaned from these companies' success stories. It is supporting its marker of cardiac ischemia with strong clinical and market development programs, aimed not just at the laboratory but also at clinicians. But the inherent complexities and nuances of the opportunity it addresses are challenging.
Advertisement

Related Content

Biosite: Building a Solid Franchise
Cardiac Diagnostics: The Horse is Out of the Barn
Cardiac Diagnostics and the Challenge of ER Testing
BNP: Can Competitors Catch Up to Biosite?
Digene's Long Road Towards a Blockbuster
Digene's Long Road Towards a Blockbuster
Biosite: Struggling to Break Out of the Diagnostics Box
Cytyc's Breakout Year
Cytyc's Breakout Year
BioSite's Play for High-Value Diagnostics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel